_______________The Other 90% of Science_______________
|
View Linked Comments |
PMID: 20110452 |
|
Fung ET Clin Chem 2010 Feb;56(2):327-9 A recipe for proteomics diagnostic test development: the OVA1 test, from bi... |
|
| Only 1 comment exists on this article. |
|
Should avoid acute phase reactants as preclinical screen |
Rank: 1 |
| BioMed Crit Comm 2011; 4:2371 | |
| Posted: Apr 20, 2011 CCID: 2371 | |
| Commentator: Anonymous | Ave. score of anonymous comments: 2.4 for 548 scored comments. |
|
Cramer et al (PMID: 21372036) re-examined and warned against some potential applications of the test panel from Fung, writing that this panel "has been [FDA-]approved to assess cancer risk in women who have an ovarian mass. This panel includes several acute phase reactants (apolipoprotein A1, transthyretin, and transferrin)...Although these are analyzed by immunoassays in the [FDA-]approved panel and by mass spectrometry in this [Cramer's] study, inclusion of acute phase reactants raises concern about use of the test to screen for preclinical disease...[it is not yet] tested and approved for this indication." Use as a preclinical screen was not part of the FDA approval. |
|
Key authors in this publication: |
| Fung ET. |
©2007-2013 BioMed Critical Commentary. All rights reserved.